search icon
  • Print
  • ShareThis
  • Text Size

In order to contribute to the discussion forum you need to be an IDSA member. If you are an IDSA member, please login now. Please read our Discussion Forum Guidelines and Terms of Use before joining.

Hepatitis C

Welcome to Hepatitis C Management Discussion Board! The Hepatitis C Management Discussion Board provides Infectious Disease Clinicians a platform to connect with colleagues to exchange information, case studies, complications, and new developments on matters concerning hepatitis C treatment and management. Certain case studies will be developed into clinical vignettes and will be available to Infectious Disease Clinicians for future reference. Please be respectful of all participants and their respective comments. Please read our Terms of Use and Discussion Forum Guidelines.


Any diagnostic or therapeutic recommendations and all opinions presented are those of the individual contributor. They do not necessarily represent the views of IDSA. The reader assumes all risks in using this information. The IDSA Hepatitis C Discussion Forum is in full compliance with HIPPA. IDSA bears no responsibility for the accuracy of participant comments and will bear no legal liability for discussion results.

If a participant wishes to post an issue on the IDSA Hepatitis C Discussion Forum, the participant is strongly urged to provide contact information for possible offline discussion via phone or email concerning the posted issue.

RSS Feed Print Category View
Gilead Next Generation Combination Pill
Posted: Monday, March 24, 2014 1:01 PM
Joined: 2/20/2013
Posts: 40

"Gilead won the race to be the first to market with an interferon-free oral therapy that can essentially wipe out all traces of the virus for a large group of patients. Now it's angling to follow up that big score with a single combo pill that can do the job for just about everyone in the megablockbuster market.

The biotech--under intense criticism for pricing Sovaldi at $84,000 in the U.S. for the 12-week treatment--posted an abstract for the upcoming meeting of the European Association for the Study of the Liver that outlined 100% cure rates among small groups of patients across 6 genotypes taking one of two doses of a Sovaldi combination treatment. The big add here is GS-5816, a next-gen NS5A inhibitor that added the essential ingredient for a new regimen that promises to eliminate any need for interferon as well as ribavirin." 

To read more, please visit:


| HIVMA | Contact Us

© Copyright IDSA 2016 Infectious Diseases Society of America

Full Site Mobile Site